Quidelortho Corp (QDEL) Stock Price & Analysis
Quidelortho Corp (QDEL) fell 3.20% to USD 16.05 as of July 25, 2026 at 03:54 UTC, according to Nexqual real-time market data.
QDEL last closed at USD 16.58; the session ranged USD 16–16.86 on volume of 877,368 shares. Market capitalization is $1.09B, with a 52-week range of USD 9.92–35.58 (NMS). Source: Nexqual, July 25, 2026 at 03:54 UTC.
Key Statistics (as of July 25, 2026 at 03:54 UTC)
| Price | USD 16.05 |
|---|---|
| Change | ▼ 3.20% (down) |
| Previous Close | USD 16.58 |
| Open | USD 16.77 |
| Day Range | USD 16 – 16.86 |
| 52-Week Range | USD 9.92 – 35.58 |
| Volume | 877,368 shares |
| Market Cap | $1.09B |
| Exchange | NMS |
Technical Analysis (QDEL)
Nexqual's technical model rates QDEL "BUY" based on 4 bullish and 2 bearish signals across 125 daily candles, as of July 25, 2026 at 03:54 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 46.47 (neutral) |
| vs SMA50 | Above (USD 14.65) |
| MACD | 0.53 (positive) |
Analyst Ratings (QDEL)
Wall Street analysts rate QDEL "None" based on 4 analysts, with a mean price target of USD 20.5 (range USD 12–38), per Nexqual as of July 25, 2026 at 03:54 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 4 |
| Mean Target | USD 20.5 |
| High Target | USD 38 |
| Low Target | USD 12 |
| Buy / Hold / Sell | 1 / 2 / 1 |
Earnings (QDEL)
| Next Earnings Date | 2026-08-06 |
|---|---|
| EPS Estimate | USD -0.04 |
| Revenue Estimate | $619.62M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.04 vs est 0.36 ▼ miss |
| 2025-12-31 | USD 0.46 vs est 0.42 ▲ beat |
| 2025-09-30 | USD 0.8 vs est 0.47 ▲ beat |
| 2025-06-30 | USD 0.12 vs est 0.01 ▲ beat |
Source: Nexqual, July 25, 2026 at 03:54 UTC.
Financials & Fundamentals (QDEL)
| Total Revenue | $2.66B |
|---|---|
| Revenue Growth (YoY) | -10.50% |
| Gross Margin | +45.18% |
| Operating Margin | -4.10% |
| Profit Margin | -45.57% |
| ROE | -49.95% |
| Debt / Equity | 155.27 |
| Current Ratio | 1.43 |
| Total Cash | $140.40M |
| Total Debt | $2.87B |
| Free Cash Flow | $208.58M |
Source: Nexqual, July 25, 2026 at 03:54 UTC.
Financial Health Score (QDEL)
Nexqual rates Quidelortho Corp's overall financial health "Weak" across five dimensions, as of July 25, 2026 at 03:54 UTC.
| Growth | Weak — Revenue -2% YoY (annual), declining |
|---|---|
| Profitability | Mixed — Gross margin 45%, operating -4% |
| Balance Sheet | Weak — $140M cash vs $2.87B debt |
| Cash Flow | Solid — FCF $209M, 8% margin |
| Efficiency | Critical — ROE -50%, ROA 0.5% |
Ownership (QDEL)
| Insider Ownership | +0.90% |
|---|---|
| Institutional Ownership | +128.20% |
| Shares Outstanding | 68.19M |
| Float | 62.11M |
| Short % of Float | +23.05% |
Source: Nexqual, July 25, 2026 at 03:54 UTC.
Leadership (QDEL)
Quidelortho Corp is led by Brian J. Blaser (age 60), President, CEO & Director, per Nexqual as of July 25, 2026 at 03:54 UTC.
| President, CEO & Director | Brian J. Blaser (age 60) |
|---|---|
| Executive VP of Research & Development and CTO | Jonathan P. Siegrist (age 43) |
| Vice President of Investor Relations | Juliet C. Cunningham |
| Vice President of Global Marketing & Corporate Communications | Lisa S. Hayes |
| Executive Vice President of Strategy & Corporate Development | Erich Wolff |
Major Backers & Investors (QDEL)
Notable institutional backers of Quidelortho Corp include Fidelity, T. Rowe Price, FMR, LLC, according to Nexqual as of July 25, 2026 at 03:54 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Fidelity | 10.45% |
| T. Rowe Price | 10.42% |
| FMR, LLC | 9.67% |
| American Century Companies Inc | 8.35% |
| Newtyn Management, Llc | 6.68% |
| Rubric Capital Management LP | 4.85% |
| Invesco | 4.57% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 23.75% |
| Vanguard Group | 17.35% |
| Dimensional Fund Advisors | 4.47% |
Source: Nexqual, July 25, 2026 at 03:54 UTC.
From Quidelortho Corp's Latest SEC 10-K Filing (filed 2026-02-19)
Key Strengths & Strategy (as disclosed to the SEC)
- QuidelOrtho Corporation provides diagnostic testing solutions.
- The company operates through Labs, Transfusion Medicine, Point of Care, and Molecular Diagnostics business units.
- The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases.
- The Point of Care business unit provides instruments and tests to provide rapid results across a continuum of POC settings.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| RGEN | Repligen Corporation | USD 131.96 | ▼ 5.8% |
| FLGT | Fulgent Genetics, Inc. | USD 19.67 | ▲ 0.72% |
| NVCR | NovoCure Limited | USD 17.65 | ▲ 13.36% |
| DXCM | DexCom, Inc. | USD 71.54 | ▲ 0.15% |
| EBS | Emergent BioSolutions Inc. | USD 7.26 | ▼ 4.22% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 03:54 UTC. This page is informational and not investment advice.